
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
The latest news for pharma industry insiders.
Panel discussion uncovers how to alter one’s digital know-how for use in temperature-controlled supply chain.
Millennials (1981–1996), burdened by health problems and costly
Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.
Healthcare organizations utilizing DoseMeRx are experiencing improved patient outcomes and hospital economic health.
Last month Enveric Biosciences, Inc. CEO Joseph Tucker, PhD, spoke with Pharmaceutical Executive about the growing #NonHallucinogenic #Psychedelic Pipeline.
Read about it here. https://lnkd.in/eYE9SRUX
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.





